Skip to main content

Breadcrumb

  1. Home

Spring 2019

Gout: ULT Therapy (Recommended for eMeasure Trial Approval)

  • Percentage of patients aged 18 and older with a diagnosis of gout and either tophus/tophi or at least two gout flares (attacks) in the past year who have a serum urate level > 6.0 mg/dL, who are prescribed urate lowering therapy (ULT)

    CBE ID
    2550e

HBIPS-2 Hours of physical restraint use

  • The total number of hours that all patients admitted to a hospital-based inpatient psychiatric setting were maintained in physical restraint.

    CBE ID
    0640

HBIPS-3 Hours of seclusion use

  • The total number of hours that all patients admitted to a hospital-based inpatient psychiatric setting were held in seclusion.

    CBE ID
    0641

HCAHPS (Hospital Consumer Assessment of Healthcare Providers and Systems) Survey

  • HCAHPS (NQF #0166) is a 29-item survey instrument that produces 10 publicly reported measures:

    6 multi-item measures (communication with doctors, communication with nurses, responsiveness of hospital staff, communication about medicines, discharge information and care transition); and

    4 single-item measures (cleanliness of the hospital environment, quietness of the hospital environment, overall rating of the hospital, and recommendation of hospital).

    CBE ID
    0166

Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)

  • Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB or ARNI therapy either within a 12-month period when seen in the outpatient setting OR at each hospital discharge

    CBE ID
    0081

Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)

  • Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB or ARNI therapy either within a 12-month period when seen in the outpatient setting OR at each hospital discharge

    CBE ID
    0081e